Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

  		Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors
Colby drugs resore therapy-sensitivity or normoxia

About Colby

Corporate History

 

Colby Pharmaceutical Company is a WARF spin-out company with signal transduction inhibitor  drugs in-licensed from the University of Wisconsin and its own Platform Technology derived drugs.  Colby in-licensed three drugs from WARF in return for equity and other payments.  Colby  has licenses for pharmaceutical products and developed other drugs in-house.  Colby operations are located in Menlo Park, California and in Madison, Wisconsin.  The company is accessing data from grants and investor funded studies.  Its lead drug is scheduled to start human prostate cancer Phase I/IIa clinical trial in 2010.